Prebiotics for irritable bowel syndrome

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 5, 2009, Pages 487-492

  Quigley, Eamonn M M ^a,b  

^a University College Cork and INFANT Centre   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Fecal microflora; Functional gastrointestinal disorder; Gut flora; Irritable bowel syndrome; Microbiota; Prebiotic; Probiotic; Trans galactooligosaccharide

Indexed keywords

MALTODEXTRIN; PLACEBO; PREBIOTIC AGENT; TRANS GALACTOOLIGOSACCHARIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ANXIETY; BACTERIAL COUNT; BACTEROIDES; BIFIDOBACTERIUM; BLOATING; CLINICAL TRIAL; CLOSTRIDIUM; CLOSTRIDIUM COCCOIDES; CLOSTRIDIUM PERFRINGENS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EUBACTERIUM; EUBACTERIUM RECTALE; FECES MICROFLORA; FLATULENCE; HUMAN; IRRITABLE COLON; NOTE; PREVOTELLA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYMPTOM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 70449724723     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.46     Document Type: Note

References (61)

1. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment. Pharmacol. Ther. 17, 643-650 (2003). (Pubitemid 36418887)
2. Kang JY. Systematic review: the influence of geography and ethnicity in irritable bowel syndrome. Aliment. Pharmacol. Ther. 21, 663-676 (2005).
3. Gwee KA. Irritable bowel syndrome in developing countries - a disorder of civilization or colonization? Neurogastroenterol. Motil. 17, 317-324 (2005).
4. Simren M, Brazier J, Coremans G et al. Quality of life and illness costs in irritable bowel syndrome. Digestion 69, 254-261 (2004). (Pubitemid 39140472)
5. Quigley EMM, Bytzer P, Jones R, Mearin F. Irritable bowel syndrome: the burden and unmet needs in Europe. Dig. Liver Dis. 38, 717-723 (2006). (Pubitemid 44362188)
6. Quigley EMM, Bergmann J-F, Bytzer P et al. An evidence-based approach to the management of irritable bowel syndrome in Europe. Eur. J. Gastroenterol. Hepatol. 19(Suppl. 1), S1-S37 (2007).
7. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 130, 1480-1491 (2006).
8. Brandt LJ, Bjorkman D, Fennerty MB et al. Systematic review on the management of irritable bowel syndrome in North America. Am. J. Gastroenterol. 97(Suppl. II), S7-S26 (2002).
9. Mayer EA. Clinical practice. Irritable bowel syndrome. N. Engl. J. Med. 358, 1692-1699 (2008).
10. Tillisch K, Wang Z, Kilpatrick L, Holschneider DP, Mayer EA. Studying the brain-gut axis with pharmacological imaging. Ann. NY Acad. Sci. 1144, 256-264 (2008).
11. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 124, 1662-1671 (2003).
12. De Giorgio R, Barbara G. Is irritable bowel syndrome an inflammatory disorder? Curr. Gastroenterol. Rep. 10, 385-390 (2008).
13. Dinan TG, Quigley EMM, Ahmed SMM et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 130, 304-311 (2006).
14. Quigley EMM. Disturbances of motility and visceral hypersensitivity in irritable bowel syndrome: biological markers or epiphenomenon. Gastroenterol. Clin. N. Am. 34, 221-233 (2005).
15. Quigley EMM. Bacteria: a new player in gastrointestinal motility disorders - infections, bacterial overgrowth and probiotics. Gastroenterol. Clin. N. Am. 36, 735-748 (2007).
16. Kassinen A, Krogius-Kurikka L, Mäkivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133, 24-33 (2007). (Pubitemid 47031125)
17. Codling C, O'Mahony L, Shanahan F, Quigley EM, Marchesi JR. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig. Dis. Sci. DOI: 10.1007/s10620-009-0934-x (2009) (Epub ahead of print).
18. Dunlop SP, Jenkins D, Neal KR et al. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment. Pharmacol. Ther. 18, 77-84 (2003). (Pubitemid 36897983)
19. Corinaldesi R, Stanghellini V, Cremon C et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof of concept study. Aliment. Pharmacol. Ther. 30(3), 245-252 (2009).
20. Pimentel M, Chow E, Lin H. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol. 98, 412-419 (2003). (Pubitemid 36232393)
21. Pimentel M, Park S, Mirocha J et al. The effect of a nonabsorbed antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann. Intern. Med. 145, 557-563 (2006). (Pubitemid 46780934)
22. Quigley EMM. A 51-year-old with irritable bowel syndrome: test or treat for bacterial overgrowth? Clin. Gastroenterol. Hepatol. 5(10), 1140-1143 (2007).
23. Vanner S. The small intestinal bacterial overgrowth irritable bowel syndrome hypothesis: implications for treatment. Gut 57, 1315-1321 (2008).
24. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-ana lysis. Clin. Gastroenterol. Hepatol. DOI: 10.1016/j. cgh.2009.06.031 (2009) (Epub ahead of print).
25. Lembo A, Zakko SF, Ferreira NL et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology 134, A545 (2008).
26. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a meta-ana lysis of randomized, controlled trials. Dis. Colon Rectum 51, 1775-1780 (2008).
27. McFarland LV, Dublin S. Meta-ana lysis of probiotics for the treatment of irritable bowel syndrome. World J. Gastroenterol. 14, 2650-2661 (2008).
28. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 9(1), 15 (2009).
29. Moayyedi P, Ford AC, Talley NJ et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut DOI: gut.2008.167270v1 (2008) (Epub ahead of print).
30. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am. J. Gastroenterol. 104(4), 1033-1049 (2009).
31. Kajander K, Krogius-Kurikka L, Rinttila T et al. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. Aliment. Pharmacol. Ther. 26, 463-473 (2007). (Pubitemid 47063154)
32. Kajander K, Myllyluoma E, Rajilić-Stojanović M et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment. Pharmacol. Ther. 27, 48-57 (2008). (Pubitemid 350212625)
33. O'Mahony L, McCarthy J, Kelly P et al. A randomized, placebo-controlled, double-blind comparison of the probiotic bacteria lactobacillus and bifidobacterium in irritable bowel syndrome (IBS): symptom responses and relationship to cytokine profiles. Gastroenterology 128, 541-551 (2005).
34. Agrawal A, Houghton LA, Morris J et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 29(1), 104-114 (2008).
35. Roberfroid M. Prebiotics: the concept revisited. J. Nutr. 137(3 Suppl. 2), S830-S837 (2007).
36. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 45(Suppl. 2), II43-II47 (1999).
37. Depeint F, Tzprtzis G, Vulevic J, L'anson K, Gibson GR. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 44171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am. J. Clin. Nutr. 87, 785-791 (2008).
38. Vos AP, M'Rabert L, Stahl B, Boehm G, Garssen J. Immunomodulatory effects and potential working mechanisms of orally applied nondigestible carbohydrates. Crit. Rev. Immunol. 27, 97-140 (2007). (Pubitemid 47015552)
39. Biarti B, Matterelli P. The family Bifidobacteria. In: The Prokaryotes. Dworkin M, Fallow S, Rosenberg E, Schieifer KH, Stackebrandt E (Eds). Springer, NY, USA, 1-70 (2001).
40. Whorwell PJ, Altringer L, Morel J et al. Efficacy of an encapsulated probiotic Bifidobacterium Infantis 35624 in women with irritable bowel syndrome. Am. J. Gastroenterol. 101, 1581-1590 (2006). (Pubitemid 43980633)
41. Guyonnet D, Chassany O, Ducrotte P et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment. Pharmacol. Ther. 26, 475-486 (2007). (Pubitemid 47063138)
42. Kim HJ, Camilleri M, McKenzie S et al. A randomized controlled trail of a probiotic, VSL#3 on gut transit and symptoms in diarrhoea-predominant IBS. Aliment. Pharmacol. Ther. 17, 895-904 (2003). (Pubitemid 36459602)
43. Kim HJ,Vazquez Roque MI, Camilleri M et al. A randomised controlled trial of probiotic combination VSL#3 and placebo in IBS with bloating: Neurogastroenterol. Motil. 17, 687-696 (2005). (Pubitemid 41400717)
44. Brandt LJ, Chey WD, Foxx-Orenstein AE et al. The American College of Gastroenterology Task force on IBS. An evidence-based position statement on the management of irritable bowel syndrome. Am. J. Gastroenterol. 104(Suppl. 1), S1-S35 (2009).
45. Ford AC, Talley NJ, Spiegel BM et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-ana lysis. Br. Med. J. 337, A2313 (2008).
46. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-ana lysis. Gut 58, 367-378 (2009).
47. Pasricha PJ. Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology 132, 2287-2290 (2007).
48. Hamilton-Miller JMT. Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microb. Ecol. Health Dis. 13, 212-216 (2001).
49. Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol. Motil. 19, 166-172 (2007). (Pubitemid 46239427)
50. Sen S, Mulan MM, Parker TJ et al. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig. Dis. Sci. 47, 2615-2620 (2002). (Pubitemid 35305475)
51. Barrett JS, Canale KE, Gearry RB, Irving PM, Gibson PR. Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J. Gastroenterol. 14, 5020-5024 (2008).
52. Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 28, 994-1002 (2008).
53. Bueno L, de Ponti F, Fried M et al. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. Neurogastroenterol. Motil. 19(1 Suppl.), 89-119 (2007). (Pubitemid 46058984)
54. Rousseaux C, Thuru X, Gelot A et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med. 13, 35-37 (2007). (Pubitemid 46067383)
55. Silk DBA, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-glucooligosaccharide on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther. 29, 508-518 (2009).
56. Andriulli A, Neri M, Loguercio C et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J. Clin. Gastroenterol. 42(Suppl. 3 Pt 2), S218-S223 (2008).
57. Colecchia A, Vestito A, La Rocca A, Pasqui F, Nikiforaki A, Festi D; Symbiotic Study Group. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol. Dietol. 52, 349-358 (2006). (Pubitemid 46166443)
58. Tsuchiya J, Barreto R, Okura R et al. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin. J. Dig. Dis. 5, 169-174 (2004). (Pubitemid 40028569)
59. Dughera L, Elia C, Navino M, Cisarò F; ARMONIA Study Group. Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms. Acta Biomed. 78, 111-116 (2007). (Pubitemid 350125133)
60. Bouhnik Y, Neut C, Raskine L et al. Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. Aliment. Pharmacol. Ther. 19, 889-899 (2004). (Pubitemid 38534818)
61. Dunne C, Murphy L, Flynn S et al. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek 76, 279-292 (1999). (Pubitemid 29440732)